The standard Trelegy Ellipta dosage for COPD in adults is 1 actuation (100 mcg/62.5 mcg/25 mcg) once daily.
The max dose of Trelegy Ellipta is 1 actuation daily—200 mcg/62.5 mcg/25 mcg for asthma and 100 mcg/62.5 mcg/25 mcg for COPD.
Trelegy Ellipta is available as a dry powder inhaler in two strengths: 100 mcg/62.5 mcg/25 mcg and 200 mcg/62.5 mcg/25 mcg.
The best time to take Trelegy Ellipta is once daily at the same time each day; do not use it as a rescue inhaler and rinse your mouth after each dose to help prevent thrush.
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name powder inhalant that combines three medications that provide triple therapy for asthma or COPD. These active ingredients include an inhaled corticosteroid (fluticasone), a long-acting anticholinergic (umeclidinium), and a long-acting beta-agonist (vilanterol). Taken as a single daily maintenance dose, Trelegy Ellipta helps to prevent asthma and COPD attacks as well as reduce the severity of the symptoms when they do occur. The dose prescribed will depend on the severity of the condition and the person’s response to the medication. Trelegy Ellipta is an oral inhaler.
The Trelegy Ellipta powder inhaler comes in two dosage strengths. There are three medications in the powder, so dosage strengths written on the packaging use the following order: fluticasone dose, umeclidinium dose, and vilanterol dose. Only the fluticasone dose varies between the two.
Dry powder inhaler (DPI): 100 micrograms (mcg)/62.5 mcg /25 mcg
Dry powder inhaler (DPI): 200 mcg/62.5 mcg /25 mcg
Healthcare professionals prescribe Trelegy Ellipta as a maintenance treatment for asthma and COPD to reduce the incidence and severity of asthma attacks or COPD flare-ups. The inhaler is not intended as a rescue medication during an active flare-up of either condition. In those cases, the use of Trelegy Ellipta is contraindicated. That is, it is never to be used for airway closure (bronchospasm) or airway swelling. Those cases require a rescue inhaler such as albuterol. Other contraindications (reasons this medication should not be used) include any hypersensitivity to any of the three active ingredients in Trelegy or to milk proteins. People who are lactose intolerant should ask the prescriber for medical advice before taking Trelegy.
Check our best Trelegy Ellipta prices
Trelegy Ellipta dosage chart |
|||
|---|---|---|---|
| Indication | Starting dosage | Standard dosage | Maximum dosage |
| Asthma | 1 actuation (100 mcg/62.5 mcg/25 mcg or 200 mcg/62.5 mcg/25 mcg dose) once per day | 1 actuation (100 mcg/62.5 mcg/25 mcg or 200 mcg/62.5 mcg/25mcg dose) once per day | 1 actuation (200 mcg/62.5 mcg/25mcg dose) once per day |
| COPD | 1 actuation (100 mcg/62.5 mcg/25 mcg dose) once per day | 1 actuation (100 mcg/62.5 mcg/25 mcg dose) once per day | 1 actuation (100 mcg/62.5 mcg/25 mcg dose) once per day |
Trelegy Ellipta combines three medications that help prevent asthma attacks and improve lung function. Fluticasone furoate is an inhaled corticosteroid (ICS) that reduces swelling in the airways. Umeclidinium (yoo-mi-cli-di-nee-um) bromide is a long-acting muscarinic antagonist (LAMA) that prevents muscles in the lungs from constricting. The dose of umeclidinium in Trelegy is always 62.5 mcg per puff. Vilanterol trifenatate is a long-acting beta2-agonist or LABA. It relaxes the muscles in the airways, promoting bronchodilation. In Trelegy, the vilanterol dose is always 25 mcg. Because all three drugs are long-acting, only one oral inhalation of Trelegy Ellipta is needed each day.
Standard Trelegy Ellipta dosage for asthma: 1 actuation (100 mcg/62.5 mcg/25 mcg or 200 mcg/62.5 mcg/25 mcg dose) daily
Maximum Trelegy Ellipta dosage for asthma: 1 actuation (200 mcg/62.5 mcg/25 mcg dose) daily
Chronic obstructive pulmonary disease (COPD) is the blanket term for two closely related medical conditions: chronic bronchitis and emphysema. Like asthma, COPD causes episodic exacerbations caused by an inflammatory response in the lung’s tissues. During the flare-ups, swelling and muscle constriction narrow the airways, causing breathing problems. The three active ingredients in Trelegy Ellipta help prevent or minimize COPD exacerbations by blocking inflammation (fluticasone) of airway passages and preventing tightening of the airway muscles (umeclidinium and vilanterol). As with asthma, doses are taken once per day.
Standard Trelegy Ellipta dosage for COPD: 1 actuation (100 mcg/62.5 mcg/25 mcg dose) once daily. This is the only strength that is FDA-approved for COPD.
Trelegy Ellipta is not FDA approved for use in children or adolescents.
No dosage adjustments are required for people with liver disease or renal (kidney) impairment. However, healthcare professionals are cautious about prescribing fluticasone to people with moderate to severe hepatic (liver) impairment, certain heart conditions, and glaucoma.
Veterinarians do not normally prescribe Trelegy for dogs or cats. Animals needing inflammatory airway disease maintenance treatment can be prescribed fluticasone HFA (inhaled corticosteroid) and salmeterol HFA, a long-acting beta-adrenergic receptor agonist. Powder inhalers are not used with animals because they are breath-activated. Pet owners may need to administer each inhalant separately.
Taking a dose with the Trelegy Ellipta inhaler is more complex than using a metered inhaler. Powdered inhalers require you to breathe in the medicine with enough force to aerosolize it. You also have to prepare each dose.
A healthcare professional should demonstrate the proper use of the inhaler. If you need a refresher, the American Lung Association has a step-by-step video tutorial on using an Ellipta dry powder inhaler.
Your healthcare provider will tell you how much medicine to use. Do not use more than directed.
Use this medicine once a day, at about the same time each day.
This medicine should come with a Medication Guide. Ask your pharmacist for a copy if you do not have one.
Each inhaler comes with only 30 doses. The package or other materials may say that there are 60 blisters or two rows of 30 blisters each. That’s because two blisters—one on each row—make up one dose. When you open the inhaler, each of the two blisters is opened.
On the inhaler, write down the day the tray was opened in the “Tray opened” field. In the “Discard date” field, write the date six weeks from the open date.
When the counter has nine doses left, the left half of the counter will turn red. That means it’s time to refill the prescription.
Do not use the inhaler after the discard date.
Throw away the inhaler in the household trash.
Do not use the inhaler if the dose count is “0.”
Do not open the cover until you are ready to take a dose. If the cover is closed without being taken, that dose w
ill be lost.
Open the cover of the inhaler all the way. It will click when completely opened and a dose has been prepared. The inhaler is ready to use. Do not close the cover until after you have taken a dose.
Exhale fully to get as much air out of the lungs as possible. Do not breathe directly toward the inhaler or into the mouthpiece.
Put the mouthpiece between your lips and close your lips firmly around it.
Do not cover the air vents with your fingers or hands.
Take one long, steady, deep breath in through your mouth.
Remove the inhaler from your mouth, hold your breath for about 3 to 4 seconds, then exhale slowly.
Close the inhaler. If needed, you may clean the mouthpiece using a dry tissue before closing the cover.
When you have finished, rinse your mouth and spit out the water. Do not swallow the water. Rinsing your mouth helps prevent thrush (fungal infection of the mouth and throat).
Store the inhaler at room temperature in a dry place protected from heat and light.
Store the Trelegy Ellipt
a package unopened at room temperature, protected from moisture, heat, and light. Open it only when ready for use.
Keep this medicine out of the reach of children.
Trelegy Ellipta is meant to work for 24 hours to prevent COPD and asthma symptoms such as wheezing, coughing, and shortness of breath. When taken once daily, a steady level of medication is maintained in the body to help prevent symptoms.
However, you may wonder how long Trelegy stays in your system if you stop taking it. Each active ingredient of Trelegy Ellipta is cleared from the body at different rates. With half-lives of 11 hours, vilanterol and umeclidinium should be completely removed from the body in less than three days after your last dose. Fluticasone has a half-life of 24 hours, so it will take about five days for the body to eliminate the fluticasone component after your last dose.
A missed dose of Trelegy Ellipta can be taken when remembered on the day it is supposed to be taken. Take the next dose as scheduled. Do not take more than one dose per day.
Trelegy Ellipta is intended for long-term use. It can be taken as long as it’s effective and the side effects are tolerable. Trelegy Ellipta may need to be discontinued if serious adverse reactions are experienced, such as:
Sudden and life-threatening airway closure (paradoxical bronchospasm)
Serious asthma-related events, including hospitalizations and death
Worsening of asthma
Chest pain
Heart rhythm or heart rate abnormalities
High blood pressure
Low potassium
Cataracts
Glaucoma
Worsening of narrow-angle glaucoma
Blurred vision
Worsening of urinary retention
Pneumonia
Loss of bone mineral density (osteoporosis)
Serious infections because of a weakened immune system
Serious allergic reactions
For COPD, the recommended dosage of 100 mcg/62.5 mcg/25 mcg per day is the same as the maximum dosage. Higher doses are not FDA-approved for COPD.
For asthma, the maximum dose is 200 mcg/62.5 mcg/25 mcg per day. Healthcare providers are urged to try alternative treatment options if that dose is ineffective. Never take more than one dose per day.
Because Trelegy Ellipta contains three drugs that have different effects, several drug interactions are possible.
Certain drugs increase Trelegy Ellipta levels in the body. Examples include the antifungal drug ketoconazole and the antiviral drug ritonavir (an ingredient of the COVID-19 treatment Paxlovid). This could cause more serious Trelegy side effects.
The antipsychotic drugs pimozide and thioridazine should never be used with Trelegy. Either of these drugs combined with Trelegy can cause dangerous heart rhythm problems. This can also occur with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, and other drugs that affect heart rhythm.
Certain types of diuretics like hydrochlorothiazide or Lasix (furosemide) can also interact with vilanterol, causing low potassium levels and/or heart rhythm problems.
Beta blockers, normally used to treat high blood pressure, will block the effects of vilanterol. Because beta blockers also can worsen asthma or COPD, people with those conditions are usually not prescribed these drugs unless no other alternatives are available.
Umeclidinium is an anticholinergic drug. These drugs have common and sometimes serious side effects that worsen if more than one type of anticholinergic drug is taken.
Trelegy Ellipta may be prescribed to pregnant women if the healthcare provider determines that the benefits outweigh the risks. Animal data does not indicate any risk of congenital disabilities, but no clinical studies exist. Vilanterol may affect delivery by changing uterine contractions. Consult your healthcare provider for medical advice if you are pregnant or planning to become pregnant.
Healthcare professionals don’t know if Trelegy Ellipta is safe to use while breastfeeding, if it is present in human breast milk, or if it affects a nursing in
fant. Consult your healthcare provider for medical advice if you are breastfeeding.
The most common adverse effects of Trelegy Ellipta are symptoms typical of an upper respiratory tract infection, such as nasal congestion, sore throat (pharyngitis), and sinus infection (sinusitis). Other common complaints include headache, back pain, urinary tract infection, constipation, and oral thrush (candidiasis).
Trelegy, GlaxoSmithKline (GSK)
Trelegy Ellipta prescribing information, DailyMed, National Library of Medicine
Anne Jacobson, MD, MPH, is a board-certified family physician, writer, editor, teacher, and consultant. She is a graduate of University of Wisconsin School of Medicine and Public Health, and trained at West Suburban Family Medicine in Oak Park, Illinois. She later completed a fellowship in community medicine at PCC Community Wellness and a master's in Public Health at the University of Illinois-Chicago. She lives with her family near Chicago.
...Los ahorros en recetas varían según la receta médica y la farmacia, y pueden alcanzar hasta un 80% de descuento sobre el precio en efectivo. Este es un plan de descuento de recetas médicas. NO es un seguro ni un plan de medicamentos de Medicare. El rango de descuentos para las recetas médicas que se brindan bajo este plan, dependerá de la receta y la farmacia donde se adquiera la receta y puede otorgarse hasta un 80% de descuento sobre el precio en efectivo. Usted es el único responsable de pagar sus recetas en la farmacia autorizada al momento que reciba el servicio, sin embargo, tendrá el derecho a un descuento por parte de la farmacia de acuerdo con el Programa de Tarifas de Descuento que negoció previamente. Towers Administrators LLC (que opera como “SingleCare Administrators”) es la organización autorizada del plan de descuento de recetas médicas ubicada en 4510 Cox Road, Suite 11, Glen Allen, VA 23060. SingleCare Services LLC (“SingleCare”) es la comercializadora del plan de descuento de prescripciones médicas que incluye su sitio web www.singlecare.com. Como información adicional se incluye una lista actualizada de farmacias participantes, así como también asistencia para cualquier problema relacionado con este plan de descuento de prescripciones médicas, comunícate de forma gratuita con el Servicio de Atención al Cliente al 844-234-3057, las 24 horas, los 7 días de la semana (excepto los días festivos). Al utilizar la aplicación o la tarjeta de descuento para recetas médicas de SingleCare acepta todos los Términos y Condiciones, para más información visita: https://www.singlecare.com/es/terminos-y-condiciones. Los nombres, logotipos, marcas y otras marcas comerciales de las farmacias son propiedad exclusiva de sus respectivos dueños.
Los artículos del blog no constituyen asesoramiento médico. Su propósito es brindar información general y no sustituyen el asesoramiento, diagnóstico ni tratamiento médico profesional. Si tiene alguna pregunta sobre una afección médica, consulte siempre a su médico u otro profesional de la salud cualificado. Si cree tener una emergencia médica, llame inmediatamente a su médico o al 911.
© 2025 SingleCare Administrators. Todos los derechos reservados
© 2025 SingleCare Administrators. Todos los derechos reservados